Cancer immunotherapy that targets immune checkpoints represent a major advance for oncology but rheumatologists will be integral to managing the autoimmune related adverse events seen in patients, an expert has told delegates. Speaking to the limbic following his talk on the scientific mechanisms and clinical features of checkpoint inhibitors for the rheumatologist Clifton O. Bingham, ...
Rheumatologists key in managing cancer immunotherapy adverse events
By Nicola Garrett
7 Nov 2017